Evidence map›Paper›PMID 37547761›Full record

ArticleOncology research2023

Identification of microbial metabolites that accelerate the ubiquitin-dependent degradation of c-Myc.

Ziyu Liu, Akiko Okano, Emiko Sanada, Yushi Futamura, Toshihiko Nogawa, Kosuke Ishikawa, Kentaro Semba, Jiang Li, Xiaomeng Li, Hiroyuki Osada and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Long-term exposure to PMScientific reports · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ziyu LiuBioprobe Application Research Unit, RIKEN CSRS, Saitama, 351-0198, Japan.
Akiko OkanoChemical Biology Research Group, RIKEN CSRS, Saitama, 351-0198, Japan.
Emiko SanadaBioprobe Application Research Unit, RIKEN CSRS, Saitama, 351-0198, Japan.
Yushi FutamuraChemical Biology Research Group, RIKEN CSRS, Saitama, 351-0198, Japan.
Toshihiko NogawaChemical Biology Research Group, RIKEN CSRS, Saitama, 351-0198, Japan.
Kosuke IshikawaJapan Biological Informatics Consortium (JBIC), Tokyo, 135-8073, Japan.
Kentaro SembaDepartment of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, 162-8480, Japan.
Jiang LiGuangdong Engineering Research Center of Oral Restoration and Reconstruction, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, China.
Xiaomeng LiKingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, China.
Hiroyuki OsadaChemical Biology Research Group, RIKEN CSRS, Saitama, 351-0198, Japan.
Nobumoto WatanabeBioprobe Application Research Unit, RIKEN CSRS, Saitama, 351-0198, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myc belongs to a family of proto-oncogenes that encode transcription factors. The overexpression of c-Myc causes many types of cancers. Recently, we established a system for screening c-Myc inhibitors and identified antimycin A by screening the RIKEN NPDepo chemical library. The specific mechanism of promoting tumor cell metastasis by high c-Myc expression remains to be explained. In this study, we screened approximately 5,600 microbial extracts using this system and identified a broth prepared from

Indexed as

Proto-Oncogene Proteins c-mycUbiquitinHumansOligomycinsReactive Oxygen Speciesoligomycin AOligomycinsProto-Oncogene Proteins c-mycReactive Oxygen SpeciesUbiquitinHigh-throughput screeningPhosphorylationReactive oxygen species

Identifiers

PMID37547761
PMCPMC10398403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.